Clinical Trial

A Study of LY4302814 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-17
Trial Details
NCT Number NCT07566338
Lead Sponsor Eli Lilly and Company
Conditions Healthy
Enrollment 150 participants
Start Date 2026-05-06
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-16